TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%
TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were up 35.8% during trading on Monday . The company traded as high as $0.12 and last traded at $0.11. Approximately 22,505 shares changed hands during trading, a decline of 56% from the average daily volume of 51,120 shares. The stock had previously closed at $0.08.
TC Biopharm（Holdings）Plc（纳斯达克股票代码：TCBPW — 获取评级）股价在周一的交易中上涨了35.8％。该公司的交易价格高达0.12美元，最后一次交易价格为0.11美元。交易期间约有22,505股易手，较平均每日交易量51,120股下降了56％。该股此前收于0.08美元。
TC Biopharm Stock Up 35.8 %
TC Biopharm股票上涨35.8％
The firm has a fifty day moving average price of $0.13 and a two-hundred day moving average price of $0.14.
该公司的五十天移动平均线价格为0.13美元，两百天移动平均线价格为0.14美元。
Institutional Trading of TC Biopharm
TC Biopharm 的机构交易
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC acquired a new position in TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 235,294 shares of the company's stock, valued at approximately $117,000.
一家对冲基金最近购买了TC Biopharm股票的新股份。根据Nantahala Capital Management LLC向美国证券交易委员会披露的最新信息，该公司在第一季度收购了TC Biopharm（Holdings）（纳斯达克股票代码：TCBPW — Get Ratinge）的新职位。该机构投资者收购了该公司235,294股股票，价值约11.7万美元。
About TC Biopharm
关于 TC Bioparm
(Get Rating)
（获取评分）
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC Biopharm（Holdings）Plc是一家临床阶段的生物制药公司，专注于开发基于其异体伽玛ΔT细胞平台的免疫疗法产品。其产品线包括OmnImmune，一种用于治疗急性髓系白血病的未改性细胞疗法；Immunistim，一种用于治疗 COVID-19 的未改性细胞疗法；用于治疗胃肠道癌的 TCB009；以及同种异体共刺激 GD-T CAR 临床前候选药物将靶向在各种实体瘤类型上表达的抗原 TCB005/TCB006。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
- 免费获取 StockNews.com 关于 TC Biopharm (TCBPW) 的研究报告
- 这就是为什么 Penny stock GreenPower 汽车公司是赢家的原因
- Comcast 所有部件的总和正在产生累积效应
- Greenbrier 公司：在 2023 年全力争取高收益
- Coty Stock 正在卷土重来
- Splunk Stock 是一款由人工智能驱动的企业 SEIM Play
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC Biopharm 每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收TC Biopharm及相关公司的最新新闻和分析师评级的简明每日摘要。